Capital Genomix, located in Rockville, MD, is a leading provider of innovative genomic and proteomic services for the biotechnology and pharmaceutical industries. Their expertise lies in the discovery, validation, and development of monoclonal antibodies, immunotherapeutic drugs, and novel biomarkers associated with cancer, aiming to advance human health.
With a focus on genomic biomarkers, cancer vaccines, and monoclonal antibodies, Capital Genomix is committed to applying cutting-edge technologies to diagnose and treat cancer, contributing to the continuous improvement of healthcare outcomes.
Generated from the website